FIELD: medicine.
SUBSTANCE: present invention relates to the field of medicine, namely to a method for in vitro targeted impact on extracellular vesicles with phosphatidylserine exposed on the surface. The specified method includes a stage of introduction of a molecule containing a gamma-carboxyglutamic acid component (hereinafter – GLA-component), wherein the specified GLA-component contains GLA-domain or its active fragment and does not contain an active catalytic domain of GLA-protein, into liquid, which may contain an extracellular vesicle. In this case, the specified GLA-domain or its active fragment are independently selected from thrombin, factor VII, factor IX, factor X, protein C, protein S, protein Z, osteocalcin, GLA-matrix protein, GAS6, transthyretin, periostin, GLA 1 enriched in proline, GLA 2 enriched in proline, GLA 3 enriched in proline, and GLA 4 enriched in proline.
EFFECT: present invention provides the use of molecules for detection of extracellular vesicles expressing phosphatidylserine, isolation of extracellular vesicles, targeted impact on extracellular vesicles, and/or loading of vesicles, for example, with therapeutic materials.
26 cl, 30 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| USEFUL LOAD DELIVERY TO STEM CELLS | 2018 |
|
RU2795155C1 |
| GLA DOMAINS AS THERAPEUTIC AGENTS | 2014 |
|
RU2705786C2 |
| GLA DOMAINS AS TARGETING AGENTS | 2014 |
|
RU2731507C1 |
| T-CELL COMPOSITIONS WITH T-CELL RECEPTOR DEFICIENCY | 2013 |
|
RU2781979C2 |
| GLA DOMAINS AS TARGETING AGENTS | 2014 |
|
RU2711091C2 |
| FACTOR VII CHIMERIC MOLECULES | 2010 |
|
RU2563231C2 |
| METHODS AND COMPOSITIONS FOR THE TREATMENT OF FABRY DISEASE | 2017 |
|
RU2788133C2 |
| MODIFIED CELLS WITH CHIMERIC ANTIGEN RECEPTOR FOR TREATING CANCER EXPRESSING CLDN6 | 2020 |
|
RU2826058C2 |
| METHODS AND COMPOSITIONS FOR TREATING FABRY DISEASE | 2020 |
|
RU2822369C2 |
| T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS | 2013 |
|
RU2653761C2 |
